Rani Therapeutics Q2 2026: RT-114 Expansion Cohort Dosed, Cash Runway Through 2027

summarizeSummary

Rani Therapeutics reported Q2 2026 results with a narrower net loss, dosed the first patients in the RT-114 Phase 1a expansion cohort, and confirmed cash runway through 2027.

check_boxKey Events · Earnings and Guidance · RANI

• Q2 2026 Financial Results

  Net loss of $8.4 million for Q2 2026, improved from $11.2 million in Q2 2025. Contract revenue of $1.7 million, primarily from the Chugai collaboration.

• RT-114 Clinical Progress

  First participants dosed in the Phase 1a expansion cohort of RT-114. Additional data expected by end of 2026; Phase 1b repeat-dose study in obesity patients expected to initiate by end of 2026 with data in 2027.

• Cash Runway Extended

  Cash, cash equivalents and marketable securities of $53.4 million as of June 30, 2026, expected to fund operations at least through 2027.

• PegBio Collaboration

  New research and development collaboration with PegBio to explore oral delivery of obesity and metabolic disease molecules using the RaniPill platform.

auto_awesomeAnalysis · RANI · Life Sciences

Rani Therapeutics reported Q2 2026 financial results with a net loss of $8.4 million, an improvement from $11.2 million a year ago. The company dosed the first participants in the Phase 1a expansion cohort of RT-114, its oral GLP-1/GLP-2 dual agonist, with additional data expected by end of 2026. Cash of $53.4 million is expected to fund operations at least through 2027, extending the runway. The company also highlighted a new collaboration with PegBio and recent executive appointments. The stock trades at $0.81, and the company faces a Nasdaq delisting notice and material weakness in internal controls, making the extended cash runway and clinical progress critical for investor confidence.